Literature DB >> 20880871

A trial of caspofungin salvage treatment in PCP pneumonia.

Darius Armstrong-James, Justin Stebbing, Laurence John, Andrew Murungi, Mark Bower, Brian Gazzard, Mark Nelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20880871     DOI： 10.1136/thx.2010.135350

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  14 in total

1.  Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.

Authors:  Xu-Qin Jiang; Lei Fang; Xiao-Dong Mei; Xiao-Jing Wang; Ming-Hong Bao
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.

Authors:  Anlei Liu; Ruixue Sun; Guanghui Cao; Xiaohang Liu; Huadong Zhu; Jing Yang
Journal:  BMC Infect Dis       Date:  2022-06-14       Impact factor: 3.667

3.  Efficacy of caspofungin combined with trimethoprim/sulfamethoxazole as first-line therapy to treat non-HIV patients with severe pneumocystis pneumonia.

Authors:  Gensheng Zhang; Miaomiao Chen; Shufang Zhang; Hongwei Zhou; Xiaozhen Ji; Jiachang Cai; Tianzheng Lou; Wei Cui; Ning Zhang
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

4.  The life cycle stages of Pneumocystis murina have opposing effects on the immune response to this opportunistic, fungal pathogen.

Authors:  Heather M Evans; Grady L Bryant; Beth A Garvy
Journal:  Infect Immun       Date:  2016-08-29       Impact factor: 3.441

5.  Echinocandins for Pneumocystis jirovecii pneumonia in non-HIV patients: A case report.

Authors:  Hui-Bin Huang; Jing-Min Peng; Bin Du
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

6.  Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

Authors:  A Luraschi; S Richard; P M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 7.  Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.

Authors:  Hongjuan Li; Haoming Huang; Hangyong He
Journal:  BMC Pulm Med       Date:  2016-11-11       Impact factor: 3.317

8.  A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole.

Authors:  Zhi-Guo Wang; Xue-Ming Liu; Qian Wang; Nan-Fang Chen; Sheng-Quan Tong
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

9.  HIV-related Pneumocystis jirovecii pneumonia managed with caspofungin and veno-venous extracorporeal membrane oxygenation rescue therapy.

Authors:  Nathaniel Lee; David Lawrence; Brijesh Patel; Stephane Ledot
Journal:  BMJ Case Rep       Date:  2017-10-04

10.  A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia.

Authors:  Mengyan Wang; Guanjing Lang; Ying Chen; Caiqin Hu; Yongzheng Guo; Ran Tao; Xiaotian Dong; Biao Zhu
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.